Half Year 2021 Aspen Pharmacare Holdings Ltd Earnings Call Transcript
Good morning, everyone. Welcome to the Aspen Interim Results Presentation for the 6 months ended 31 December 2020, presented at the JPMorgan Healthcare Conference.
A few important disclosure notes here for your later consideration at the front of the presentation. And I'm going to kick off with the financial review.
To start with the financial highlights. We're very pleased with the strong organic revenue growth that we've generated over the first 6 months of this financial year, 6% constant exchange rate growth, 17% in full reported terms, up at ZAR 18.6 billion. That's been translated into really robust earnings growth when one considers all the challenges that we've encountered over the period with the COVID crisis around us.
Normalized EBITDA is up 2% in constant exchange rate terms. But as we'll discuss later, the underlying growth in EBITDA at constant exchange rate is actually 5%, up 11% in reported terms. Normalized HEPS is up 7% in constant
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
